Publications

US FTC Continues Effort To Eliminate Orange Book’s Improper Patent Listings

Quoted, Pink Sheet

Chad Landmon, Hatch-Waxman & Biologics Chair, discusses the FTC's crusade to delist improper listings from the FDA’s Orange Book and the impact on the generic drug industry.